NTRK2 R458G
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene NTRK2
Variant R458G
Impact List missense
Protein Effect gain of function
Gene Variant Descriptions NTRK2 R458G lies within the cytoplasmic domain of the Ntrk2 protein (UniProt.org). R458G results in cell surface expression and receptor dimerization similar to wild-type Ntrk2 but leads to increased phosphorylation of Ntrk2, Akt, and Erk, and IL3-independent growth in culture (PMID: 32315394).
Associated Drug Resistance
Category Variants Paths

NTRK2 mutant NTRK2 act mut NTRK2 R458G

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_001018064.3
gDNA chr9:g.84752061A>G
cDNA c.1372A>G
Protein p.R458G
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
XM_005252004.3 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_017014751.3 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_001369539.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_017014758.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_005252003.4 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_017014754.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_001369533.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_006180.4 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_017014755.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_001369541.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_001369542.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_001018065.2 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_017014755.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_017014760.3 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_017014751.2 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_005252003.3 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_017014753.3 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_001018066.2 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_005252007.4 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_001007097.3 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_001369545.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_001369549.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_011518718.3 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_001369537.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_001018064.2 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_017014759.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_011518718.4 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_001369544.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_005252004.2 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_017014757.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_047423432.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_017014753.2 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_017014752.2 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_017014752.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_001369547.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_001369548.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_001018066.3 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_017014756.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_001018065.2 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_005252006.4 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_005252001.4 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_047423433.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_001369540.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_001018064.3 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_017014761.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_017014760.2 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_011518720.3 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_001007097.2 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_001369543.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_006180.6 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_001369532.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
NM_001369538.1 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38
XM_005252001.3 chr9:g.84752061A>G c.1372A>G p.R458G RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
NTRK2 R458G hematologic cancer sensitive Entrectinib Preclinical - Cell culture Actionable In a preclinical study, Rozlytrek (entrectinib) decreased Ntrk2 phosphorylation and viability and increased apoptosis in a transformed cell line expressing NTRK2 R458G in culture (PMID: 32315394). 32315394
NTRK2 R458G hematologic cancer sensitive Foretinib Preclinical - Cell culture Actionable In a preclinical study, Foretinib (GSK1363089) inhibited viability of transformed cells expressing NTRK2 R458G in culture (PMID: 32315394). 32315394
NTRK2 R458G hematologic cancer sensitive Cabozantinib Preclinical - Cell culture Actionable In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited viability of transformed cells expressing NTRK2 R458G in culture (PMID: 32315394). 32315394
NTRK2 R458G hematologic cancer sensitive Crizotinib Preclinical - Cell culture Actionable In a preclinical study, Xalkori (crizotinib) inhibited viability of transformed cells expressing NTRK2 R458G in culture (PMID: 32315394). 32315394
NTRK2 R458G hematologic cancer sensitive Crenolanib Preclinical - Cell culture Actionable In a preclinical study, Crenolanib (CP-868596) inhibited viability of transformed cells expressing NTRK2 R458G in culture (PMID: 32315394). 32315394
NTRK2 R458G hematologic cancer sensitive Ponatinib Preclinical - Cell culture Actionable In a preclinical study, Iclusig (ponatinib) inhibited viability of transformed cells expressing NTRK2 R458G in culture (PMID: 32315394). 32315394
NTRK2 R458G hematologic cancer sensitive Larotrectinib Preclinical - Cell culture Actionable In a preclinical study, Vitrakvi (larotrectinib) inhibited viability of transformed cells expressing NTRK2 R458G in culture (PMID: 32315394). 32315394